Management of obsessive-compulsive disorder with fluvoxamine extended release

References

• GoodmanWKWardHKablingerAFluvoxamine in the treatment of obsessive-compulsive disorder and related conditionsJ Clin Psychiatry199758Suppl 532499184625
   PubMed Web of Science ®Google Scholar
• van HartenJOverview of the pharmacokinetics of fluvoxamineClin Pharmacokinet199529Suppl 1198846617
   PubMedGoogle Scholar
• Dell’OssoBAllenAHollanderEFluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorderExpert Opin Pharmacother200562727274016316311
   PubMed Web of Science ®Google Scholar
• BareggiSRMundoEDell’OssoBThe use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disordersExpert Opin Drug Metab Toxicol2007374175317916059
   PubMed Web of Science ®Google Scholar
• FontenelleLFNascimentoALMendlowiczMVAn update on the pharmacological treatment of obsessive-compulsive disorderExpert Opin Pharmacother20078556358317376013
   PubMed Web of Science ®Google Scholar
• LeonardHLSwedoSELenaneMCA double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorderArch Gen Psychiatry1991489229271929762
   PubMed Web of Science ®Google Scholar
• BarrLCGoodmanWKAnandAAddition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorderAm J Psychiatry1997154129312959286191
   PubMed Web of Science ®Google Scholar
• GoodmanWKPriceLHDelgadoPLSpecificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramineArch Gen Psychiatry1990475775852112374
   PubMed Web of Science ®Google Scholar
• MavissakalianMTurnerSMMichelsonLTricyclic antidepressants in obsessive-compulsive disorder: antiobsessionals or antidepressant agents? IIAm J Psychiatry19851425725763885761
   PubMed Web of Science ®Google Scholar
• AckermanDLGreenlandSMultivariate meta-analysis of controlled drug studies for obsessive-compulsive disorderJ Clin Psychopharmacol20022230931712006902
   PubMed Web of Science ®Google Scholar
• PiccinelliMPiniSBellantuonoCEfficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic reviewBr J Psychiatry19951664244437795913
   PubMed Web of Science ®Google Scholar
• El MansariMBlierPMechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorderProg Neuropsychopharmacol Biol Psychiatry20063036237316427729
   PubMed Web of Science ®Google Scholar
• MorescoRMColomboCFazioFEffects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET studyNeuroimage20001245246510988039
   PubMed Web of Science ®Google Scholar
• SuharaTTakanoASudoYHigh levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomographyArch Gen Psychiatry20036038639112695316
   PubMed Web of Science ®Google Scholar
• TakanoASuharaTIchimiyaTTime course of in vivo 5-HTT transporter occupancy by fluvoxamineJ Clin Psychopharmacol4200626218819116633150
   PubMed Web of Science ®Google Scholar
• TakahashiHYahataNKoedaMEffects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI studyNeuroimage200527991100115978846
   PubMed Web of Science ®Google Scholar
• DenysDZoharJWestenbergHGThe role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidenceJ Clin Psychiatry200465Suppl 14111715554783
   PubMed Web of Science ®Google Scholar
• MorescoRMPietraLHeninMFluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patientsNeuropsychopharmacology20073219720517019408
   PubMed Web of Science ®Google Scholar
• KimCHCheonKAKooMSDopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitorsNeuropsychobiology2007551566217657168
   PubMed Web of Science ®Google Scholar
• HashimotoKIshiwataKSigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticalsCurr Pharm Des2006123857387617073684
   PubMed Web of Science ®Google Scholar
• StahlSMThe sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognitionJ Clin Psychiatry2008691673167419200426
   PubMed Web of Science ®Google Scholar
• NaritaNHashimotoKTomitakaSInteractions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brainEur J Pharmacol19963071171198831113
   PubMed Web of Science ®Google Scholar
• IshikawaMIshiwataKIshiiKHigh occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503Biol Psychiatry20076287888317662961
   PubMed Web of Science ®Google Scholar
• EgashiraNHaradaSOkunoRInvolvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetineEur J Pharmacol200756314915417349995
   PubMed Web of Science ®Google Scholar
• KorffSHarveyBHAnimal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacologyPsychiatr Clin North Am20062937139016650714
   PubMed Web of Science ®Google Scholar
• DeVaneCLGillHSClinical pharmacokinetics of fluvoxamine: applications to dosage regimen designJ Clin Psychiatry199758Suppl 57149184622
   PubMed Web of Science ®Google Scholar
• PeruccaEGattiGSpinaEClinical pharmacokinetics of fluvoxamineClin Pharmacokinet1994271751907988100
   PubMed Web of Science ®Google Scholar
• LuvoxCR2008Prescribing InformationPalo AltoJazz Pharmaceuticals, Inc
   Google Scholar
• StraussWLLaytonMEHayesCE19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorderAm J Psychiatry19971545165229090339
   PubMed Web of Science ®Google Scholar
• ClaassenV1983Review of the animal pharmacology and pharmacokinetics of fluvoxamineBr J Clin Pharmacol15Suppl 3349S355S6407497
   PubMed Web of Science ®Google Scholar
• StraussWLLaytonMEDagerSRBrain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopyAm J Psychiatry19981553803849501749
   PubMed Web of Science ®Google Scholar
• StahlSM2005Essential psychopharmacology: the prescriber’s guideNew YorkCambridge University Press
   Google Scholar
• SpinaESantoroVD’ArrigoCClinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an updateClin Ther2008301206122718691982
   PubMed Web of Science ®Google Scholar
• IronsJFluvoxamine in the treatment of anxiety disordersNeuropsychiatr Dis Treat2005128929918568110
   PubMedGoogle Scholar
• PerseTLGreistJHJeffersonJWFluvoxamine treatment of obsessive-compulsive disorderAm J Psychiatry1987144154315483120604
   PubMed Web of Science ®Google Scholar
• JenikeMAHymanSBaerLA controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theoryAm J Psychiatry1990147120912152143637
   PubMed Web of Science ®Google Scholar
• GreistJHJenikeMARobinsonDEfficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trialEur J Clin Res19957195204
   Google Scholar
• GoodmanWKKozakMJLiebowitzMTreatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trialInt Clin Psychopharmacol19961121298732310
   PubMed Web of Science ®Google Scholar
• CottrauxJMollardEBouvardMExposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followupPsychiatry Res19934963758140182
   PubMed Web of Science ®Google Scholar
• HohagenFWinkelmannGRasche-RüchleHCombination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre studyBr J Psychiatry199835Suppl7178
   Web of Science ®Google Scholar
• FreemanCPTrimbleMRDeakinJFFluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparisonJ Clin Psychiatry1994553013058071291
   PubMed Web of Science ®Google Scholar
• KoranLMMcElroySLDavidsonJRFluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparisonJ Clin Psychopharmacol1996161211298690827
   PubMed Web of Science ®Google Scholar
• MilanfranchiARavagliSLensiPA double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol1997121311369248868
   PubMed Web of Science ®Google Scholar
• MundoEMainaGUslenghiCMulticentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol200015697610759337
   PubMed Web of Science ®Google Scholar
• MundoERouillonFFigueraMLFluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramineHum Psychopharmacol20011646146812404554
   PubMed Web of Science ®Google Scholar
• SteinDJSpadacciniEHollanderEMeta-analysis of pharmacotherapy trials for obsessive-compulsive disorderInt Clin Psychopharmacol19951011187622800
   PubMed Web of Science ®Google Scholar
• RavizzaLBarzegaGBellinoSDrug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRI)Psychopharmacol Bull1996321671738927668
   PubMed Web of Science ®Google Scholar
• MundoEBareggiSRPirolaRLong-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled studyJ Clin Psychopharmacol1997174109004050
   PubMed Web of Science ®Google Scholar
• RauchSLShinLMDoughertyDDPredictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation studyNeuropsychopharmacology20022778279112431852
   PubMed Web of Science ®Google Scholar
• Ho PianKLvan MegenHJRamseyNFDecreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxaminePsychiatry Res2005138899715766633
   PubMed Web of Science ®Google Scholar
• O’ConnorKTodorovCRobillardSCognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled studyCan J Psychiatry199944647110076743
   PubMed Web of Science ®Google Scholar
• KordonAKahlKGBroocksAClinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-upEur Arch Psychiatry Clin Neurosci2005255485015538591
   PubMed Web of Science ®Google Scholar
• HollanderEKoranLMGoodmanWKA double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorderJ Clin Psychiatry20036464064712823077
   PubMed Web of Science ®Google Scholar
• BogettoFAlbertUMainaGSertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimenEur Neuropsychopharmacol1218118612007668
   PubMed Web of Science ®Google Scholar
• DeVaneCLImmediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nauseaJ Clin Psychiatry200364Suppl 18141914700450
   PubMed Web of Science ®Google Scholar
• TollefsonGDRampeyAHJrPotvinJHA multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorderArch Gen Psychiatry1994515595678031229
   PubMed Web of Science ®Google Scholar
• ZoharJJudgeRParoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study InvestigatorsBr J Psychiatry19961694684748894198
   PubMed Web of Science ®Google Scholar
• GreistJChouinardGDuBoffEDouble-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorderArch Gen Psychiatry1995522892957702445
   PubMed Web of Science ®Google Scholar
• KoranLMPallantiSPaivaRSPulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorderEur Neuropsychopharmacol199881211269619690
   PubMed Web of Science ®Google Scholar
• WestenbergHGSteinDJYangHA double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorderJ Clin Psychopharmacol200424495514709947
   PubMed Web of Science ®Google Scholar
• Luvox2004Prescribing InformationPalo AltoJazz Pharmaceuticals, Inc
   Google Scholar
• DavidsonJYaryura-TobiasJDuPontRFluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorderJ Clin Psychopharmacol20042411812515206657
   PubMed Web of Science ®Google Scholar